Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
r4v3BnvMX6rJT7dC